[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613492":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":31,"collaborators":20,"id":33,"slug":20,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":20,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":20,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":20,"overallStatus":53,"whyStopped":20,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":20},{"fullName":5,"class":6},"Southern College of Optometry","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"acoltremon 0.003%.","EXPERIMENTAL","Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Restasis at 28 days post-treatment compared to baseline.",[13],"Drug: acoltremon 0.003%",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","acoltremon 0.003%","Participants who are using restasis will be switched to acoltremon 0.003%",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Chris Lievens, OD","CONTACT","901-722-3330","clievens@sco.edu",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Quentin Franklin, BS, BA","6592064188","QuentinFranklin@uab.edu",{"type":32,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100613492",false,"NCT07267299","Switching From Restasis to TRYPTYR","Efficacy of Switching Participants Treated With Restasis to TRYPTYR","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Have a history of DED for at least the past 6 months.\n* Are currently using Restasis as directed by their eye care provider for ≥1 month.\n* Participant intends to stop Restasis in the near future because and expressed dissatisfaction with effectiveness of Restasis in reducing dry eye symptoms..\n* Are symptomatic as determined with the Eye Dryness visual analog scale (VAS) (Score ≥50), SPEED (≥7), and have an abnormal Schirmer test score \\[≥2 to \\\u003C10 mm\u002F5 min\\]) at Screening\u002FBaseline.\n* Have corrected distance visual acuity of 20\u002F100 or better.\n* Willing to discontinue contact lens wear throughout the study.\n\nExclusion Criteria:\n\n* Have a systemic health condition that is known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).\n* Have a history of ocular surgery within the past 12 months.\n* Have a history of severe ocular trauma, active ocular infection or inflammation that is not dry eye related.\n* Punctal plugs in place for \\\u003C 3 months and\u002For Lacrifill in place for \\> 5 months.\n* Have ever used Accutane or are currently using ocular medications (must washout from all dry eye medications\u002Ftreatments at least 1 week before entry, except for Restasis).\n* Use of artificial tears within 2 hours prior to the baseline visit or during the study.\n* Are pregnant or breast feeding.\n* Have had a physical meibomian gland treatment withing 1 month of enrollment.\n* Have a condition or be in a situation, which in the investigator's opinion, may put the participant at significant risk, may confound the results, or may significantly interfere with their study participation.","ALL","18 Years","100 Years",{"count":43,"type":44},100,"ESTIMATED","INTERVENTIONAL",[47],"PHASE4","Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Restasis at 28 days post-treatment compared to baseline. Dry eye disease (DED) is a prevalent condition that commonly affects patients of working age in addition to the elderly. DED is a complex condition that results in ocular symptoms such as dryness and burning and signs such as decreased tear production (aqueous deficient DED) or increased tear evaporation (evaporative DED). Unfortunately, there is not a perfect correlation between DED signs and symptoms, which makes diagnosis and timely treatment challenging.",[50,51,52],"Dry Eye","Eye Diseases","Chronic Dry Eye","NOT_YET_RECRUITING","2025-11-25",{"date":56,"type":57},"2025-12-05","ACTUAL",{"date":59,"type":44},"2025-12-01",{"date":61,"type":44},"2026-05-15",{"name":5,"class":6}]